http://streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 12 Jun 2026 06:52:14 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Anixa+Biosciences+%28ANIX%29/26638080.html <p>H.C. Wainwright analyst Yi Chen reiterated a Buy rating and $7.00 price target on Anixa Biosciences (NASDAQ: ANIX).</p><p>The analyst commented: "Yesterday, Anixa Biosciences filed its financial results for the fiscal 2Q26 ending on April 30, 2026. Net loss was $2.5M, or ($0.07) per share. Cash flows from operating activities were ($1.7M). At the end of April 2026, the company had $13.7M in cash and investments, which may fund operations through 2027, in our view. We believe the company may continue to use its ATM facility to raise capital. Importantly, the company reported updated survival observations in May 2026 from the http://www.streetinsider.com/Analyst+Comments/H.C.+Wainwright+Reiterates+Buy+Rating+on+Anixa+Biosciences+%28ANIX%29/26638080.html Fri, 12 Jun 2026 06:52:14 -0400 ANIX http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html <div class="xn-content"> <p class="prntac"><i>Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongoing Phase 1 clinical trial</i></p><p class="prntac"><i>Breast cancer vaccine presentation to include final Phase 1 data showing all major primary endpoints were met and protocol-defined immune responses in 74% of participants</i></p><p class="prntac"><i>Presentations highlight Anixa's clinical progress and collaborations with leading cancer research institutions</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 11, 2026</chron></span> /PRNewswire/ -- <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4709186-1&amp;h=3793925043&amp;u=http%3A%2F%2Fwww.anixa.com%2F&amp;a=Anixa+Biosciences%2C+Inc." target="_blank" rel="nofollow"><span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span></a> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that two of its http://www.streetinsider.com/PRNewswire/Anixa+Biosciences+Announces+Presentations+of+Two+Clinical-Stage+Immunotherapy+Programs+at+New+York+Academy+of+Sciences%27+Frontiers+in+Cancer+Immunotherapy+Symposium/26633499.html Thu, 11 Jun 2026 09:05:00 -0400 A.32727947 A.50204218 ANIX O.00048376 O.00048394 O.00049302 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Anixa+Biosciences+Inc+++++For%3A+Apr+30/26630115.html si-local-file:///var/storage/secattach/20260610/26630115.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Anixa+Biosciences+Inc+++++For%3A+Apr+30/26630115.html Wed, 10 Jun 2026 16:16:00 -0400 ANIX O.00049302 http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Anixa+Biosciences+Inc+++++For%3A+Apr+30/26630115.html si-local-file:///var/storage/secattach/20260610/26630115.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++Anixa+Biosciences+Inc+++++For%3A+Apr+30/26630115.html Wed, 10 Jun 2026 16:16:00 -0400 ANIX O.00049302 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html <p>Anixa Biosciences Inc. (NASDAQ: ANIX) announced the Canadian Intellectual Property Office issued a Notice of Allowance for a patent covering aspects of its ovarian cancer vaccine technology.</p> <p>The patent, exclusively licensed from Cleveland Clinic, covers methods of administering an immunogenic composition containing nucleic acid encoding the anti-Müllerian hormone receptor 2 polypeptide to generate an immune response for ovarian cancer prevention or treatment.</p> <p>The company's ovarian cancer vaccine is being developed through collaboration between Cleveland Clinic and the National Cancer Institute. The vaccine targets AMHR2, a protein expressed in normal ovaries before menopause and in certain ovarian cancers.</p> <p>The Canadian allowance expands Anixa's international http://www.streetinsider.com/Corporate+News/Anixa+receives+Canadian+patent+allowance+for+ovarian+cancer+vaccine/26580323.html Mon, 01 Jun 2026 09:00:49 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513 http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html <div class="xn-content"> <p class="prntac"><i>Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer</i></p><p><span class="legendSpanClass"><location value="LU/us.ca.sanjse" idsrc="xmltag.org" >SAN JOSE, Calif.</location></span>, <span class="legendSpanClass"><chron>June 1, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:ANIX" idsrc="xmltag.org" >Anixa Biosciences, Inc.</span> ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual Property Office (CIPO) has issued a Notice of Allowance for a patent covering key aspects of Anixa's ovarian cancer vaccine technology.</p> <div class="PRN_ImbeddedAssetReference" id="DivAssetPlaceHolder1"> http://www.streetinsider.com/Press+Releases/Anixa+Biosciences+Strengthens+International+Patent+Protection+for+Ovarian+Cancer+Vaccine+Technology+with+Canadian+Notice+of+Allowance/26580297.html Mon, 01 Jun 2026 09:00:00 -0400 A.40958841 A.60001765 ANIX O.00049302 O.20738543 O.36670513